## 507212781 04/01/2022

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT7259631 Stylesheet Version v1.2

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
ANTHONY CHARARA	03/30/2022
MARK DEACON SHAW	03/30/2022

#### **RECEIVING PARTY DATA**

Name:	TISSUE REPAIR LTD
Street Address:	LEVEL 10, 255 PITT STREET
City:	SYDNEY
State/Country:	AUSTRALIA
Postal Code:	2000

#### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	17390809

### **CORRESPONDENCE DATA**

**Fax Number:** (858)777-5425

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 858-729-0800

**Email:** docketing@arciplaw.com

Correspondent Name: ARC PATENTS

Address Line 1: 5749 LA JOLLA BLVD

Address Line 4: LA JOLLA, CALIFORNIA 92037

ATTORNEY DOCKET NUMBER: 20176-P020

NAME OF SUBMITTER: JOSEPH J. MAYO

SIGNATURE: /JJM53288/

DATE SIGNED: 04/01/2022

#### **Total Attachments: 3**

source=20220401\_Assignment\_Substitute\_SIGNED\_20176-P020#page1.tif source=20220401\_Assignment\_Substitute\_SIGNED\_20176-P020#page2.tif source=20220401\_Assignment\_Substitute\_SIGNED\_20176-P020#page3.tif

507212781 PATENT REEL: 059478 FRAME: 0335

Our Ref. No. 20176-P020

ASSIGNMENT DOCUMENT

THIS ASSIGNMENT is made and entered into by and between Anthony

CHARARA and Mark Deacon SHAW (ASSIGNOR(S)), and Tissue Repair Ltd an

entity existing under the laws of the AUSTRALIA and having a place of business at

Level 10, 255 Pitt Street, Sydney, NSW 2000, AUSTRALIA ("ASSIGNEE").

WHEREAS, the ASSIGNOR(S) conceived new and useful inventions described

in the patent application entitled: "ISOLATED BIOLOGICAL POLYSACCHARIDE

COMPOUND, METHODS OF USE AND METHODS OF MANUFACTURE

**THEREOF**" to be filed, and subsequently filed, on July 30, 2021 with the United States

Patent and Trademark Office and having a Serial No. of 17/390,809 (ASSIGNEE or its

agents or representatives have the right to indicate the filing date and serial number

assigned to the U.S. Patent Application(s) this document relates to, as further described

below).

WHEREAS, the ASSIGNOR(S) are obligated to transfer and desirous of

transferring the entire right, title, and interest in the Inventions and the Applications and

all rights of priority resulting therefrom to ASSIGNEE and ASSIGNEE is desirous of

acquiring the entire right, title, and interest in and to the Inventions and the Applications

and all rights of priority resulting therefrom from the ASSIGNOR(S).

NOW THEREFORE, for consideration the adequacy and receipt of which is

hereby acknowledged, and other good and valuable consideration, the ASSIGNOR(S)

hereby irrevocably sell, transfer, and assign the full and exclusive right, title and interest

in and to the Inventions and Applications including any causes of action relating thereto

and the right to collect damages recoverable thereon, the right to sue for infringement of

any patents issuing therefrom and to collect damages including the right to sue for past

infringement therefore, and all rights to continuing, continuations-in-part, divisional,

improvement, substitute, renewal, reissue, re-examined and all other applications for

Page 1 of 3

PATENT 059478 FRAM

REEL: 059478 FRAME: 0336

Our Ref. No. 20176-P020

Letters Patent which have been or shall be filed in the United States and all foreign

countries on said Inventions or taking priority from any patent application describing the

Invention; and all original, reissued or re-examined patents which have been or shall be

issued in the United States and all foreign countries on said Inventions; and in and to all

rights of priority resulting from the filing of said Applications.

ASSIGNOR(S) hereby authorize and request the Director of the U.S. Patent and

Trademark office and all foreign Patent Offices to issue Patents for the subject matter

assigned herein to ASSIGNEE for the sole and exclusive benefit of ASSIGNEE to the

full end of the term for which said Patent may be granted as fully and entirely as the same

would have been held by ASSIGNOR(S) had this assignment and sale not been made.

In the event ASSIGNEE is unable, after reasonable effort, to secure

ASSIGNORS' signatures on any documents relating to protection or maintenance of the

Inventions or Applications, whether because of ASSIGNORS' physical or mental

incapacity or for any other reason, ASSIGNOR(S) hereby irrevocably designate and

appoint ASSIGNEE and its duly authorized officers and agents as their agent and

attorney-in-fact, to act for and on their behalf to execute and file any application or

applications and to do all other lawfully permitted acts to further the prosecution,

issuance, and maintenance of the Inventions or Applications or improvements to the

Inventions or Applications with the same legal force and effect as if personally executed

by ASSIGNOR(S).

ASSIGNOR(S) hereby covenant with ASSIGNEE, its successors, assigns and

legal representatives that no assignment, grant, mortgage, license or other agreement

affecting the right to the Inventions conveyed herein has been made to another by the

undersigned and that the full right to convey as herein expressed is possessed by

ASSIGNOR(S) free and clear of all liens, pledges, charges and encumbrances. In cases

where such information is missing ASSIGNOR(S) grant ASSIGNEE and agents or

representatives of ASSIGNEE the right to modify this document to indicate the filing

date and serial number assigned to the U.S. Patent Application(s) this document relates

Page 2 of 3

PATENT

to. This Assignment may be executed in counterparts, each of which shall be deemed and original. ACCEPTED AND AGREED TO:

# ASSIGNOR(S)

Inventor Signature	Date	
Signature: Anthony CHARARA	30/03/2022	

Inventor Signature	Date
Signature:	
and the second s	30/03/2022
Anthony Charara	
Director	
Tissue Repair Limited	
Signed on behalf of Mark Deacon SHAW	
Pursuant to:	
"Consulting Agreement TR Therapeutics – Mark	
Deacon-Shaw EXECUTED" dated 12/08/2013	
Mark Deacon SHAW	